These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19704131)

  • 1. Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.
    Yang G; Paintsil E; Dutschman GE; Grill SP; Wang CJ; Wang J; Tanaka H; Hamasaki T; Baba M; Cheng YC
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4640-6. PubMed ID: 19704131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.
    Nitanda T; Wang X; Kumamoto H; Haraguchi K; Tanaka H; Cheng YC; Baba M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3355-60. PubMed ID: 16048947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate.
    Yang G; Wang J; Cheng Y; Dutschman GE; Tanaka H; Baba M; Cheng YC
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2035-42. PubMed ID: 18391035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly selective action of triphosphate metabolite of 4'-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT.
    Yang G; Dutschman GE; Wang CJ; Tanaka H; Baba M; Anderson KS; Cheng YC
    Antiviral Res; 2007 Mar; 73(3):185-91. PubMed ID: 17109975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
    Paintsil E; Dutschman GE; Hu R; Grill SP; Lam W; Baba M; Tanaka H; Cheng YC
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3870-9. PubMed ID: 17724147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.
    Sohl CD; Kasiviswanathan R; Kim J; Pradere U; Schinazi RF; Copeland WC; Mitsuya H; Baba M; Anderson KS
    Mol Pharmacol; 2012 Jul; 82(1):125-33. PubMed ID: 22513406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
    White KL; Margot NA; Wrin T; Petropoulos CJ; Miller MD; Naeger LK
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
    García-Lerma JG; MacInnes H; Bennett D; Reid P; Nidtha S; Weinstock H; Kaplan JE; Heneine W
    J Virol; 2003 May; 77(10):5685-93. PubMed ID: 12719561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells.
    Wang X; Tanaka H; Baba M; Cheng YC
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3317-24. PubMed ID: 19470503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations.
    Oliveira M; Moisi D; Spira B; Cox S; Brenner BG; Wainberg MA
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1683-5. PubMed ID: 19223637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.
    Smith RA; Raugi DN; Wu VH; Leong SS; Parker KM; Oakes MK; Sow PS; Ba S; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7437-46. PubMed ID: 26392486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro.
    Drosopoulos WC; Prasad VR
    J Virol; 1998 May; 72(5):4224-30. PubMed ID: 9557711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants.
    Tanaka H; Haraguchi K; Kumamoto H; Baba M; Cheng YC
    Antivir Chem Chemother; 2005; 16(4):217-21. PubMed ID: 16130520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.
    Andreatta KN; Goodman DD; Miller MD; White KL
    Antimicrob Agents Chemother; 2015; 59(6):3441-9. PubMed ID: 25824231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
    Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
    J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.